CD98 and T Cell Activation
Kurihara, Takeshi Tokushima University
Arimochi, Hideki Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Bhuyan, Zaied Ahmed Tokushima University
Ishifune, Chieko Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Tsumura, Hideki National Research Institute for Child Health and Development
Ito, Morihiro Chubu University
Ito, Yasuhiko Chubu University
Kitamura, Akiko Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Maekawa, Yoichi Tokushima University
Yasutomo, Koji Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Upon their recognition of antigens presented by the MHC, T cell proliferation is vital for clonal expansion and the acquisition of effector functions, which are essential for mounting adaptive immune responses. The CD98 heavy chain (CD98hc, Slc3a2) plays a crucial role in the proliferation of both CD4+ and CD8+ T cells, although it is unclear if CD98hc directly regulates the T cell effector functions that are not linked with T cell proliferation in vivo. Here, we demonstrate that CD98hc is required for both CD4+ T cell proliferation and Th1 functional differentiation. T cell-specific deletion of CD98hc did not affect T cell development in the thymus. CD98hc-deficient CD4+ T cells proliferated in vivo more slowly as compared with control T cells. C57BL/6 mice lacking CD98hc in their CD4+ T cells could not control Leishmania major infections due to lowered IFN-γ production, even with massive CD4+ T cell proliferation. CD98hc-deficient CD4+ T cells exhibited lower IFN-γ production compared with wild-type T cells, even when comparing IFN-γ expression in cells that underwent the same number of cell divisions. Therefore, these data indicate that CD98hc is required for CD4+ T cell expansion and functional Th1 differentiation in vivo, and suggest that CD98hc might be a good target for treating Th1-mediated immune disorders.
© 2015 Kurihara et al. This is an open access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|DOI (Published Version)|
|URL ( Publisher's Version )|
pone_10_10_e0139692.pdf 1.63 MB